LENZ Therapeutics, Inc. (LENZ) — Financial statements
Income statement, balance sheet, and cash flow for LENZ Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 19 | 0.00 | 0.00↓100.0% | 15 | 0.00 | |
| Cost of Revenue | 0.71↑1115.5% | 0.06 | 0.00 | 0.00↓100.0% | 0.73 | |
| Gross Profit | 18↑31794.8% | -0.06 | 0.00↓100.0% | 15↑2143.6% | -0.73 | |
| Operating Expenses | ||||||
| R&D Expenses | 19↓37.4% | 30↓49.9% | 60↑181.7% | 21↓44.3% | 38 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 91↑216.0% | 29↑122.4% | 13↑196.6% | 4↓80.0% | 22 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 110↑87.0% | 59↓19.2% | 72↑184.2% | 25↓57.3% | 60 | |
| Total Costs & Expenses | 110↑88.1% | 59↓19.1% | 72↑184.2% | 25↓57.8% | 60 | |
| Operating Results | ||||||
| Operating Income | -91↓55.5% | -59↑19.1% | -72↓590.9% | -10↑82.7% | -60 | |
| Depreciation & Amortization | 0.29↑394.8% | 0.06↑286.7% | 0.02↑87.5% | 0.01↓98.9% | 0.73 | |
| EBITDA | -91↓82.8% | -50↑31.4% | -72↓591.3% | -10↑85.0% | -70 | |
| EBIT | -91↓83.1% | -50↑31.3% | -72↓590.9% | -10↑85.2% | -71 | |
| Interest & Other Income | ||||||
| Net Interest Income | 10↑14.1% | 9↑290.7% | 2 | 0.00 | 0.00 | |
| Interest Income | 10↑14.1% | 9↑290.7% | 2 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -9 | 0.00 | 0.00↓100.0% | 10 | |
| Other Income / Expenses | 10↑7.6% | 9↑287.5% | 2↑11910.5% | 0.02↑100.2% | -10 | |
| Income Before Tax | -82↓64.0% | -50↑29.1% | -70↓570.4% | -10↑85.2% | -71 | |
| Income Tax Expense | 0.50↑50100.0% | 0.00↑100.6% | -0.18↓151.6% | 0.35 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -82↓65.0% | -50↑28.9% | -70↓547.2% | -11↑84.7% | -71 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -82↓65.0% | -50↑28.9% | -70↓547.2% | -11↑84.7% | -71 | |
| Bottom-Line Net Income | -82↓65.0% | -50↑28.9% | -70↓547.2% | -11↑84.7% | -71 | |
| EPS (Basic) | -2.85↓21.8% | -2.34↑84.7% | -15.30↓18.7% | -12.89↓51.0% | -8.54 | |
| EPS (Diluted) | -2.85↓21.8% | -2.34↑84.7% | -15.30↓18.7% | -12.89↓51.0% | -8.54 | |
| Weighted Average Shares | 29↑35.4% | 21↑161.3% | 8↑3.9% | 8↓5.4% | 8 | |
| Weighted Average Diluted Shares | 29↑35.4% | 21↑161.3% | 8↑3.9% | 8↓5.4% | 8 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.